Daiichi Sankyo and Merck announced FDA has granted breakthrough therapy designation for their drug raludotatug deruxtecan for treating certain types of ovarian cancer. The designation was based on data from a phase 1 study and ongoing phase 2/3 study. The drug is intended for adults with platinum-resistant epithelial ovarian, primary peritoneal, or fallopian tube cancers who have previously been treated with bevacizumab.

Read more at Nasdaq: Daiichi Sankyo, Merck Say Raludotatug Deruxtecan Granted Breakthrough Therapy Designation